231 related articles for article (PubMed ID: 34007154)
1. Consolidation Treatment and Long-Term Prognosis of Rituximab in Minimal Change Disease and Focal Segmental Glomerular Sclerosis.
Lin L; Wang W; Wu Y; Xie J; Li X; Pan X; Zhang W; Xu J; Cai Y; Ren H; Chen N
Drug Des Devel Ther; 2021; 15():1945-1953. PubMed ID: 34007154
[TBL] [Abstract][Full Text] [Related]
2. Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: a systematic review and meta-analysis.
Hansrivijit P; Cheungpasitporn W; Thongprayoon C; Ghahramani N
BMC Nephrol; 2020 Apr; 21(1):134. PubMed ID: 32293308
[TBL] [Abstract][Full Text] [Related]
3. Rituximab treatment for relapsing minimal change disease and focal segmental glomerulosclerosis: a systematic review.
Kronbichler A; Kerschbaum J; Fernandez-Fresnedo G; Hoxha E; Kurschat CE; Busch M; Bruchfeld A; Mayer G; Rudnicki M
Am J Nephrol; 2014; 39(4):322-30. PubMed ID: 24751753
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Rituximab for Minimal Change Disease and Focal Segmental Glomerulosclerosis with Frequently Relapsing or Steroid-Dependent Nephrotic Syndrome in Adults: A Chinese Multicenter Retrospective Study.
Lan L; Lin Y; Yu B; Wang Y; Pan H; Wang H; Lou X; Lang X; Zhang Q; Jin L; Yang Y; Xiao L; Chen J; Han F
Am J Nephrol; 2024; 55(1):25-36. PubMed ID: 37963441
[TBL] [Abstract][Full Text] [Related]
5. Rituximab in adult patients with multi-relapsing/steroid-dependent minimal change disease and focal segmental glomerulosclerosis: a report of 5 cases.
Kronbichler A; König P; Busch M; Wolf G; Mayer G; Rudnicki M
Wien Klin Wochenschr; 2013 Jun; 125(11-12):328-33. PubMed ID: 23624956
[TBL] [Abstract][Full Text] [Related]
6. Rituximab treatment for refractory nephrotic syndrome in adults: a multicenter retrospective study.
Ma X; Fang L; Sheng L; Zhou X; Bai S; Zang X; Wang Y; Li M; Lv Z; Zhong Q; Yang X; Wang Y; Hu Y; Yan D; Shi Y; Chen H; Li J; Tao M; Zhuang S; Wang Y; Liu N
Ren Fail; 2023 Dec; 45(1):2237124. PubMed ID: 37482915
[TBL] [Abstract][Full Text] [Related]
7. Use of Rituximab as an Off-Label Medication in Glomerular Diseases: Clinical Perspective.
AlSahow A; Al-Muhaiteeb A; Nawar H; AlHelal B; AlYousef A; Abdallah E; AbuShall A; Elmekawi S; Meshal B; AlQallaf A; AlRajab H
Med Princ Pract; 2022; 31(2):133-141. PubMed ID: 35021170
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of low-dose rituximab in minimal change disease and prevention of relapse.
Zhang J; Zhao H; Li X; Qian R; Gao P; Lu S; Ma Z
BMC Nephrol; 2023 Apr; 24(1):112. PubMed ID: 37101300
[TBL] [Abstract][Full Text] [Related]
9. Successful management of post-transplant focal segmental glomerulosclerosis with therapeutic plasma exchange and rituximab.
Koutroutsos K; Charif R; Moran L; Moss J; Cook T; Roufosse C; Pusey C; Taube D; Loucaidou M
Clin Exp Nephrol; 2019 May; 23(5):700-709. PubMed ID: 30637591
[TBL] [Abstract][Full Text] [Related]
10. High-Dose Rituximab Ineffective for Focal Segmental Glomerulosclerosis: A Long-Term Observation Study.
Roccatello D; Sciascia S; Rossi D; Alpa M; Naretto C; Radin M; Barreca A; Fenoglio R; Baldovino S; Menegatti E
Am J Nephrol; 2017; 46(2):108-113. PubMed ID: 28700988
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of repeat-dose rituximab maintenance therapy for minimal change disease in adults.
Taguchi S; Ohtake T; Mochida Y; Ishioka K; Moriya H; Hidaka S; Kobayashi S
Clin Exp Nephrol; 2020 Dec; 24(12):1132-1139. PubMed ID: 32761467
[TBL] [Abstract][Full Text] [Related]
12. Rituximab and low-dose cyclosporine combination therapy for steroid-resistant focal segmental glomerulosclerosis.
Suyama K; Kawasaki Y; Miyazaki K; Kanno S; Ono A; Suzuki Y; Ohara S; Hosoya M
Pediatr Int; 2016 Mar; 58(3):219-223. PubMed ID: 26275234
[TBL] [Abstract][Full Text] [Related]
13. Rituximab treatment in adults with refractory minimal change disease or focal segmental glomerulosclerosis.
Ren H; Lin L; Shen P; Li X; Xie J; Pan X; Zhang W; Chen N
Oncotarget; 2017 Nov; 8(55):93438-93443. PubMed ID: 29212162
[TBL] [Abstract][Full Text] [Related]
14. Repetitive administration of rituximab can achieve and maintain clinical remission in patients with MCD or FSGS.
Osterholt T; Todorova P; Kühne L; Ehren R; Weber LT; Grundmann F; Benzing T; Brinkkötter PT; Völker LA
Sci Rep; 2023 Apr; 13(1):6980. PubMed ID: 37117201
[TBL] [Abstract][Full Text] [Related]
15. Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown?
Gauckler P; Shin JI; Alberici F; Audard V; Bruchfeld A; Busch M; Cheung CK; Crnogorac M; Delbarba E; Eller K; Faguer S; Galesic K; Griffin S; Hrušková Z; Jeyabalan A; Karras A; King C; Kohli HS; Maas R; Mayer G; Moiseev S; Muto M; Odler B; Pepper RJ; Quintana LF; Radhakrishnan J; Ramachandran R; Salama AD; Segelmark M; Tesař V; Wetzels J; Willcocks L; Windpessl M; Zand L; Zonozi R; Kronbichler A;
Autoimmun Rev; 2020 Nov; 19(11):102671. PubMed ID: 32942039
[TBL] [Abstract][Full Text] [Related]
16. Emerging therapeutic strategies for minimal change disease and focal and segmental glomerulosclerosis.
Siligato R; Cernaro V; Nardi C; De Gregorio F; Gembillo G; Costantino G; Conti G; Buemi M; Santoro D
Expert Opin Investig Drugs; 2018 Nov; 27(11):839-879. PubMed ID: 30360670
[TBL] [Abstract][Full Text] [Related]
17. Our experience with rituximab therapy for adult-onset primary glomerulonephritis and review of literature.
Kong WY; Swaminathan R; Irish A
Int Urol Nephrol; 2013 Jun; 45(3):795-802. PubMed ID: 22798030
[TBL] [Abstract][Full Text] [Related]
18. Age of Onset and Disease Course in Biopsy-Proven Minimal Change Disease: An Analysis From the Cure Glomerulonephropathy Network.
Chen DP; Helmuth ME; Smith AR; Canetta PA; Ayoub I; Mucha K; Kallash M; Kopp JB; Gbadegesin R; Gillespie BW; Greenbaum LA; Parekh RS; Hunley TE; Sperati CJ; Selewski DT; Kidd J; Chishti A; Reidy K; Mottl AK; Gipson DS; Srivastava T; Twombley KE;
Am J Kidney Dis; 2023 Jun; 81(6):695-706.e1. PubMed ID: 36608921
[TBL] [Abstract][Full Text] [Related]
19. Rituximab for minimal-change nephrotic syndrome in adulthood: predictive factors for response, long-term outcomes and tolerance.
Guitard J; Hebral AL; Fakhouri F; Joly D; Daugas E; Rivalan J; Guigonis V; Ducret F; Presne C; Pirson Y; Hourmant M; Glachant JC; Vendrely B; Moranne O; Faguer S; Chauveau D
Nephrol Dial Transplant; 2014 Nov; 29(11):2084-91. PubMed ID: 24920841
[TBL] [Abstract][Full Text] [Related]
20. Rituximab in adult minimal change disease and focal segmental glomerulosclerosis.
Kronbichler A; Bruchfeld A
Nephron Clin Pract; 2014; 128(3-4):277-82. PubMed ID: 25401966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
